Functional egg protein hydrolysates via targeted pre-treatment, enzymatic hydrolysis and membrane fractionation

Overview

This technology platform uses a three-step process to turn egg proteins into functional hydrolysates: pre-treatment, enzymatic hydrolysis and membrane fractionation. Egg proteins often have compact, stable structures that resist enzymatic breakdown, making it difficult to obtain ingredients with consistently tailored functionality. The approach addresses this by making proteins more accessible to enzymes before hydrolysis, then controlling breakdown and purifying the resulting protein and peptide fractions.

Egg white and other egg-protein streams can yield products with a range of functional properties, depending on molecular size and degree of hydrolysis. The key value is flexibility: fractions can be used individually as purpose-built ingredients or recombined into blends to meet a target food application.

Technical specifications

Key features:

• Pre-treatment: Homogenization or pulsed electric field treatment unfolds proteins, increases accessibility for enzymes and inactivates protease inhibitors that would otherwise reduce hydrolysis efficiency.
• Enzymatic hydrolysis: Commercial proteases such as Neutrase and Flavourzyme can be used alone or as cocktails to reach the desired degree of hydrolysis while retaining important characteristics such as solubility.
• Membrane fractionation: Hydrolysate mixtures are passed over membranes with different molecular-weight cut-offs to produce purified fractions with specific molecular weight ranges and functional properties.
• Blend design: Fractions can be used individually or combined to create ingredient profiles that closely match the target requirement in a food system.
• Prediction tools (future validation): Computational and AI-based screening is expected to predict peptide sequences from common proteases and flag peptides of interest, such as reaching antioxidant activity, before physical experimentation.

Technology readiness level

The process builds on previous research that shows pre-treatment makes proteins easier for enzymes to act on and more than twenty years of peptide hydrolysis research. Purified hydrolysates such as egg-derived ovalbumin hydrolysates have already been produced and tested for activities such as reduced blood pressure. For this application-defined platform, the contributing is planned to mature from laboratory validation to pilot-scale production.

Pilot validation will include production of a 500 g hydrolysate batch and characterization of the hydrolysate fractions and blends in application-oriented tests. The technology is therefore at a mid-stage: the core processing tools have scientific and training support, but the integrated egg-protein workflow is still being upgraded, and final commercial production will require further scale-up and application-specific optimization.